Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268442 | 0.83 | ATM (0.48) | MTNR1BCFTRSLC2A1KCNH2KDM4D | |
| SCHEMBL3376051 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL3410554 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL3410549 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL3376049 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL4281088 | 0.79 | SLC2A1 (0.69) | SLC2A1KCNH2KDM4D | |
| SCHEMBL13145838 | 0.78 | DDR2 (0.44) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL13145890 | 0.77 | KCNH2 (0.49) | MTNR1AMTNR1BSLC2A1KCNH2 | |
| SCHEMBL5259099 | 0.76 | LMNA (0.48) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL13652558 | 0.76 | ATM (0.42) | CFTRSLC2A1KCNH2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | MTNR1A 1464/4885MTNR1B 1125/4885CFTR 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.